You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 3, March 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (24)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Psychopharmacology
 •Suicide
 •Alert me on articles by topic

Suicidal Risk in Antidepressant Drug Trials

Arch Gen Psychiatry. 2006;63:246-248.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Suicide is the third leading cause of death in the United States at ages 10 through 24 years.1 Major depressive disorder and depressive phases of bipolar I and II disorders are associated with most suicides. Among patients with these disorders, suicide rates are 20-times or more higher than the international general population rate of about 0.015% per year.2-3 In addition, a lower ratio of attempted-to-completed suicide (approximately 5:1) than in the general population (approximately 25:1) suggests greater lethality of intent or methods of attempts among patients with mood disorder.2, 4-5

The major public health significance of suicide and its strong association with depressive disorders encourage consideration of effects of psychiatric treatments on suicidal risk. Only clozapine has a Food and Drug Administration–approved indication for reducing risk of suicidal behavior in patients with schizophrenia, based on evidence that includes a controlled comparison with olanzapine treatment.6-8 There is also evidence for major reduction . . . [Full Text of this Article]


AUTHOR INFORMATION
Ross J. Baldessarini, MD; Maurizio Pompili, MD; Leonardo Tondo, MD


RELATED ARTICLE

Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Tarek A. Hammad, Thomas Laughren, and Judith Racoosin
Arch Gen Psychiatry. 2006;63(3):332-339.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Suicide in the Elderly: A Psychological Autopsy Study in a North Italy Area (1994-2004)
Pompili et al.
AJGP 2008;16:727-735.
ABSTRACT | FULL TEXT  

Strategies for the Prevention and Treatment of Suicidal Behavior
Clayton and Auster
Focus 2008;6:15-21.
ABSTRACT | FULL TEXT  

Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents
Gibbons et al.
Am. J. Psychiatry 2007;164:1356-1363.
ABSTRACT | FULL TEXT  

Restrictions on Antidepressant Medications for Children: A Review of Medicaid Policy
Fischer et al.
Psychiatr. Serv. 2007;58:135-138.
ABSTRACT | FULL TEXT  

The Relationship Between Antidepressant Prescription Rates and Rate of Early Adolescent Suicide
Gibbons et al.
Am. J. Psychiatry 2006;163:1898-1904.
ABSTRACT | FULL TEXT  

Do Antidepressants Increase Suicidality in Younger Patients?
JWatch Psychiatry 2006;2006:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.